There is a growing understanding of the overlap between therapeutic cancer targets and the healthy cardiovascular system. An increasing number of oncology drugs are now known to potentially affect the myocardium and other cardiovascular structures adversely. Preclinical development is tasked to assess the on-target and off-target effects of therapeutic candidates, and to develop compound-specific algorithms and biomarker programmes to support safe clinical development.
An improved understanding of these mechanisms and their early detection will enable the early development of diagnostic and mitigation strategies in the clinic, allowing high-need cancer treatment to reach and benefit patients. As patient survivals increase in oncology, risk-based safety surveillance is needed to identify late onset cardiotoxicity.
By their nature, oncology compounds are potentially toxic. Enhancing the interaction between cardiology and oncology safety experts at each step of the development chain is vital to facilitate optimal outcomes in oncology.
Featured Topics:
The preclinical domain: Prevention and/or mitigation of cardiotoxicity -are we there yet?
Identification of onco-cardiotoxicity during early phase clinical trials
Mechanistic cardiotoxicity: How far have we progressed?
Translating preclinical understanding to the clinic
Mitigation of adverse effects on the CV system: Developing and implementing strategies
Who Should Attend:
Cardiologists, oncologists, clinical investigators, primary care physicians and nurse practitioners
Preclinical toxicologists and scientists with an interest in cardiotoxicity
Drug development experts, clinical research managers and associates
Drug safety and pharmacovigilance managers
Pharmaceutical physicians and medical managers
Clinical and non-clinical safety pharmacology scientists
Regulatory affairs officers
Biostatisticians, statistical data modellers and data managers
Outsourcing
An improved understanding of these mechanisms and their early detection will enable the early development of diagnostic and mitigation strategies in the clinic, allowing high-need cancer treatment to reach and benefit patients. As patient survivals increase in oncology, risk-based safety surveillance is needed to identify late onset cardiotoxicity.
By their nature, oncology compounds are potentially toxic. Enhancing the interaction between cardiology and oncology safety experts at each step of the development chain is vital to facilitate optimal outcomes in oncology.
Featured Topics:
The preclinical domain: Prevention and/or mitigation of cardiotoxicity -are we there yet?
Identification of onco-cardiotoxicity during early phase clinical trials
Mechanistic cardiotoxicity: How far have we progressed?
Translating preclinical understanding to the clinic
Mitigation of adverse effects on the CV system: Developing and implementing strategies
Who Should Attend:
Cardiologists, oncologists, clinical investigators, primary care physicians and nurse practitioners
Preclinical toxicologists and scientists with an interest in cardiotoxicity
Drug development experts, clinical research managers and associates
Drug safety and pharmacovigilance managers
Pharmaceutical physicians and medical managers
Clinical and non-clinical safety pharmacology scientists
Regulatory affairs officers
Biostatisticians, statistical data modellers and data managers
Outsourcing
